Can #chemotherapy be avoided for some patients with breast cancer? That is exactly what the #NoLEEta trial #GBG121 is investigating. The study focuses on patients with hormone receptor-positive, HER2-negative early breast cancer and an intermediate risk of #recurrence. #GBG

The #BMBC registry (#GBG79) collects data from #patients with breast cancer and brain #metastases. The registry looks at disease course, diagnosis and treatment, as well as the biological characteristics that may contribute to the development of brain metastases. www.gbg.de/en/trials/bmbc

What does a flamingo have to do with breast cancer research? More than you might think! The #Flamingo-01 trial (#GBG111) is investigating an immunological treatment approach for patients with #HER2/neu-positive breast cancer and an increased risk of #recurrence. www.gbg.de/en/trials/fl...

A new analysis of the #Penelope-B clinical trial cohort, published in Modern Pathology, investigated #HER2 protein expression and mRNA profiles in 723 residual breast #cancer tumors following #neoadjuvant chemotherapy. 📄 Read the publication: www.modernpathology.org/article/S089... #GBG

Deepen your knowledge. Stay up to date. Learn together. Looking to expand your knowledge of breast cancer and the latest developments in research? Discover our workshops and find the right learning opportunity for you. Find out more: workshops.gbg.events #GBG

A clinical trial may end. A patient’s story does not! What happens years after participating in a clinical trial? How are patients doing in the long term? The Patient Self-Reported Outcome Registry (#GBG071) was established to follow former clinical trial participants over the long term.

New publication from the #DESIREE (#GBG86) study: In patients with HR-positive/HER2-negative metastatic breast cancer, circulating GPC4 levels showed a significant non-linear association with overall survival, with BMI acting as an important effect modifier. link.springer.com/article/10.1...

Breast cancer and pregnancy – two topics that are rarely considered together. For women facing both at the same time, however, they are inseparable. The #BCP registry (#GBG 29) collects data on the diagnosis and treatment of breast cancer during pregnancy. www.gbg.de/en/trials/pr...

When chemotherapy is considered, does it always have to come first? That was the question behind the randomized #PADMA trial in patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer. Read the publication here: www.sciencedirect.com/science/arti...

Does every patient with breast cancer need chemotherapy? The answer is not necessarily the same for everyone. The #GeparPiPPa trial (#GBG105) is investigating a biomarker-driven treatment approach for patients with HR+, HER2+ and PIK3CA-mutated early breast cancer. www.gbg.de/en/trials/ge...

Why does a treatment sometimes stop working? This is where the MOMENTUM registry (GBG 108) comes in: The aim is to understand how tumors change over the course of the disease and which molecular mechanisms contribute to treatment resistance. www.gbg.de/studien/mome...

⛔ Need professional support with your clinical trial ❓ ➡️ From study design and planning to implementation and data management ⬅️ If you are planning a clinical trial or looking for an experienced partner to help bring your research project forward, get in touch with us.

What if a clinical trial does not show the result we hoped for? That is not a failure. It is an important scientific finding. The international phase III NSABP-B-59/GBG-96-GeparDouze trial has now been published in Nature Medicine. Read more here: www.nature.com/articles/s41...

October is Breast Cancer Awareness Month. At the @GBG, we develop and conduct clinical trials with high quality to answer these questions – together with patients, physicians, study centres and research partners. #BreastCancerAwarenessMonth #BreastCancer #GBG #ClinicalTrials #CancerResearch

#GAIN-2 #GBG68: More intensive #chemotherapy, better response does not necessarily mean better #survival. Read the publication: www.nature.com/articles/s41... #ClinicalTrials #Neoadjuvant #adjuvant #GBG

New publication in Nature Medicine: The phase 3 NSABP B-59/GeparDouze trial, jointly conducted by the #NSABP Foundation and #GBG. An important step toward more precise, biomarker-driven treatment in TNBC: the right immunotherapy for the right patient. Nature Medicine: www.nature.com/articles/s41...

📢 Small residual disease, big impact: lymph node #micrometastases after neoadjuvant therapy were linked to >2.5x higher recurrence risk and >3x higher mortality risk in a new #GBG/AGO-B analysis. #BreastCancer #AxillarySurgery #CancerResearch www.thebreastonline.com/article/S096... #BreastCancer

🧬 New in Annals of Oncology: Incorporating #sTILs into #PREDICT prognostic model improves risk assessment for early-stage #TNBC. Updated model, PREDICT_sTILs, may help identify patients who can safely avoid chemotherapy while maintaining excellent outcomes. www.annalsofoncology.org/article/S092...

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival

Stromal tumor-infiltrating lymphocytes (sTILs) are a strong prognostic marker in patients with triple-negative breast cancer (TNBC). We aimed to incorporate sTILs into the PREDICT model for women with...

annalsofoncology.org

New #Publication: #PADMA provides first prospective randomized evidence that #palbociclib + #ET is superior to standard single-agent chemotherapy as first-line treatment for HR+/HER2- metastatic breast cancer in terms of treatment durability and disease control. www.sciencedirect.com/science/arti...

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study

PADMA is a prospective, randomized, open-label, multicenter phase IV study comparing palbociclib and endocrine therapy (ET) with mono-chemotherapy (CT…

sciencedirect.com

#ESMOBC: new analyses from the Phase III #INAVO120 trial evaluating inavolisib in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive/HER2-negative endocrine-resistant advanced breast cancer. Visit our website: www.gbg.de/en/news/deta...

New data from #ESMOBC The #GeparPiPPa study showed a manageable safety profile for chemotherapy-free treatment with #inavolisib, endocrine therapy, and dual #HER2 blockade in HR+/HER2+/PIK3CA-mutant early breast cancer, supporting more personalized treatment strategies. #BreastCancer #GBG www.gbg.de

New insights from #ESMOBC: A modified Sinn regression grade combining tumor response and nodal status improved prognostic stratification after neoadjuvant therapy in breast cancer, supporting more personalized treatment decisions. #BreastCancer #GBG Visit our website: www.gbg.de

🧬 Today on #WorldCancerDay our thoughts are with everyone who is affected directly or indirectly by #cancer. At the same time, we want to highlight the enormous potential that #science now offers - especially for people with #breastcancer: #Molecular #Testing www.gbg.de/en/news/deta...

🔔 Reminder: Join us on March 12–13, 2026 for the 23rd Annual Scientific Meeting 2026 #ASM, a 2-day international #conference focusing on breast cancer. 👉 Registration is open now – make sure to secure the Early Bird rate by January 15: extern.gbg.events

🔍 #SABCS2025: #INSEMA Trial – #Radiotherapy Analysis (presented by Guido Hildebrandt) Today’s presentation offered important insights into how radiotherapy was actually applied among patients undergoing breast-conserving surgery with or without sentinel lymph node biopsy #SLNB in the INSEMA trial.

#SABCS2025 Update: #INSEMA – Secondary results presented by Toralf Reimer INSEMA Rando2 adds robust data on the oncological #safety of omitting cALND in patients with positive SLNB, under conditions of strict regional nodal irradiation #RNI and #radiotherapy quality assurance.

📣 Meet #GBG at #SABCS2025 – Highlights for December 11! A full and inspiring third day at the SABCS brought important new insights into #axillary #surgery, #radiotherapy strategies, #translational #biomarkers, and international collaborations shaping the future of #breast #cancer care.

At #SABCS2025, new translational results from the #NSABP B-59/GBG-96- #GeparDouze trial were presented by Carsten Denkert, highlighting how #TIL levels and molecular #TNBC subtypes shape response to #neoadjuvant immune-chemotherapy. ➡️ Full details are available here: www.gbg.de/news/detail/...

📢 Hot from the Press: Now published in #NEJM! We are excited to share that the pivotal DESTINY-Breast05 data „Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer“ presented by Sibylle Loibl at #SABCS2025, is now available. 🔗 Read the full NEJM article: www.nejm.org/doi/full/10....

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | NEJM

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...

nejm.org

#SABCS2025: S. Loibl presented additional efficacy and safety data from the DESTINY-Breast05 trial, evaluating trastuzumab deruxtecan vs trastuzumab emtansine as post-NACT for pts with high-risk HER2-positive early breast cancer who did not achieve a pCR after standard NACT and anti-HER2 therapy.